Press Releases

• July 16, 2026
  Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
  Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients.

• July 13, 2026
  Grünenthal brings the ‘Kinder-Lebens-Lauf’ to Aachen – a powerful statement in support of children’s hospice
  By organising its own staging of the 2026 Kinder-Lebens-Lauf, Grünenthal has today sent a clear signal of its support for critically ill children and their families.

• July 8, 2026
  Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
  Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).

• July 1, 2026
  Grünenthal certified as family-friendly employer for sixth time
  Grünenthal certified as family-Grünenthal has once again been recognised for its commitment to improving the work-life balance of its employees. As part of the ‘berufundfamilie’ audit, the Aachen-based pharmaceutical company’s certificate has been extended for a further three years with a distinction.

• June 29, 2026
  Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist
  Grünenthal announced today that the company successfully concluded a Phase I trial evaluating the safety and tolerability of its proprietary NOP agonist.

• March 27, 2026
  Grünenthal achieves outstanding financial results in 2025, powered by strategic growth, integration and diversification
  Grünenthal, a global leader in pain management and research, has published exceptional 2025 financial results, marking a year of record-high profitability and operational excellence.

• March 5, 2026
  Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
  Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.

• March 2, 2026
  Grünenthal takes full ownership of Grünenthal Meds
  Grünenthal today announced that it has acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, taking full ownership of the company formed through a joint venture and its portfolio of established medicines.

• February 24, 2026
  Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
  Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza1, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain.

• February 18, 2026
  Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
  Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).